Latest News on MIRM

Financial News Based On Company


Advertisement
Advertisement

After exercising 2,000 options, Mirum Pharmaceuticals (MIRM) director sells 2,000 shares at $92.28.

https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-6a8f8d955fb1.html
Mirum Pharmaceuticals director Saira Ramasastry exercised 2,000 stock options at an exercise price of $28.97 per share on November 16, 2026. On the same day, Ramasastry sold 2,000 common shares of MIRM at $92.28 per share, as part of a Rule 10b5-1 Plan adopted in August 2026. After these transactions, Saira Ramasastry holds 15,000 stock options and zero common shares directly.

A 2,000-share sale is planned by Mirum Pharmaceuticals (MIRM) director Saira Ramasastry.

https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-59dd775b4ad1.html
Mirum Pharmaceuticals director Saira Ramasastry has filed a Form 144, indicating an intended sale of 2,000 common shares with an aggregate market value of $184,560.00, scheduled for approximately November 16, 2026. The filing also notes a concurrent cash-paid stock option exercise for 2,000 shares acquired on the same date. The plan for this transaction under Rule 10b5-1 was adopted on August 10, 2026.

No portfolio tops 5% within Janus Henderson’s reported Mirum Pharmaceuticals (MIRM) stake.

https://www.stocktitan.net/sec-filings/MIRM/schedule-13g-a-mirum-pharmaceuticals-inc-amended-passive-investment-d-1d7d3f6bc65a.html
Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 8.5% in Mirum Pharmaceuticals, Inc. (MIRM), totaling 5,537,330 common shares as of September 30, 2026. The filing clarifies that while Janus Henderson's asset managers exercise shared voting and dispositive power for client-managed portfolios, none of these individual portfolios own more than 5% of MIRM common stock. The asset managers disclaim rights to dividends and sale proceeds, which are instead received by the managed portfolios.

Weekly Recap: Phase 3 endpoint met and 2026 revenue outlook $715M-$720M

https://www.tradingview.com/news/tradingview:325d93f3f1365:0-weekly-recap-phase-3-endpoint-met-and-2026-revenue-outlook-715m-720m/
Mirum Pharmaceuticals (NASDAQ:MIRM) announced that its drug brelovitug met the primary endpoint in a Phase 3 hepatitis delta trial with no new safety signals, and the company plans to seek U.S. approval in the first half of 2027. Mirum reported $521 million in 2025 product sales and projects 2026 revenue to be between $715 million and $720 million. Citigroup maintained a Buy rating on MIRM and raised its price target to $194 from $184.

Form 4 Mirum Pharmaceuticals Inc: Eric Bjerkholt (CFO) For: 11 September

https://uk.investing.com/news/stock-market-news/form-4-mirum-pharmaceuticals-inc-eric-bjerkholt-cfo-for-11-september-93CH-4983505
This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc, specifically detailing an insider transaction by Eric Bjerkholt, the company's CFO, on September 11th. Such filings provide transparency into the buying and selling of company stock by insiders. The brief news item indicates this is a routine financial disclosure without providing further details on the nature or value of the transaction.
Advertisement

Mirum Pharmaceuticals Inc (08D.SG) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/08D.SG/dividends/
This Yahoo Finance page provides comprehensive information on Mirum Pharmaceuticals Inc (08D.SG) stock. It includes real-time quotes, a detailed performance chart showing various timeframes, and key financial statistics such as previous close, day's range, 52-week range, and volume. The page also presents a performance overview comparing the stock's returns against the S&P 500 benchmark for different periods.

Form 144 MIRUM PHARMACEUTICALS For: 14 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-mirum-pharmaceuticals-for-14-november-93CH-2808153
Investing.com reported on a Form 144 filing for Mirum Pharmaceuticals, pertaining to activity on November 14th. The article, published on November 15, 2026, contains the official filing information. This content is primarily a record of the Form 144.

Form 144 MIRUM PHARMACEUTICALS For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-mirum-pharmaceuticals-for-14-november-93CH-4958837
Investing.com reported on November 14, 2026, about a Form 144 filing by Mirum Pharmaceuticals (MIRM). The article briefly mentions the filing and the company's stock performance on that day, showing a +0.71% change. This is a standard notification of a Form 144 filing, which indicates an insider's intent to sell restricted or control securities.

Form 4 Mirum Pharmaceuticals Inc: Laura Brege (Director) For: 11 November

https://au.investing.com/news/stock-market-news/form-4-mirum-pharmaceuticals-inc-laura-brege-director-for-11-november-93CH-4770919
This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc., indicating a transaction by Laura Brege, a director of the company, on November 11. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's insiders. The content of the filing itself is not detailed in the article, which primarily serves as an announcement of the filing's existence.

Mirum Pharmaceuticals director Laura Brege sells $1.33M in shares

https://www.investing.com/news/insider-trading-news/mirum-pharmaceuticals-director-laura-brege-sells-133m-in-shares-93CH-5027091
Laura Brege, a director at Mirum Pharmaceuticals (NASDAQ:MIRM), sold approximately $1.33 million in common stock on November 11, 2026, after exercising stock options. These sales involved 14,167 shares at weighted average prices between $94.05 and $94.74. Following the transactions, Brege directly holds 15,703 shares, and the company's stock, despite a strong 31.6% return over the past year, is considered slightly overvalued by InvestingPro.
Advertisement

Can Mirum Pharmaceuticals (MIRM) Justify A Premium To Sales Here?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/can-mirum-pharmaceuticals-mirm-justify-a-premium-to-sales-he
Mirum Pharmaceuticals (MIRM) has seen a significant share price increase, prompting questions about its current valuation relative to sales. Despite a P/S ratio of 9.2x, which is below industry averages, the market appears to be aligning its expectations with the company's future revenue potential, especially following positive Phase 3 data for brelovitug. Analysts largely view MIRM as undervalued by 38%, based on anticipated successful label expansions and new product launches.

Director Laura Ann Brege sold 14,167 shares in Mirum Pharmaceuticals (MIRM).

https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-5d128fe7213c.html
Mirum Pharmaceuticals director Laura Ann Brege reported the sale of 14,167 common shares on November 11, 2026, with an aggregate market value of $1,334,673.07. This transaction followed her acquisition of the same number of shares through a cash-paid stock option exercise on the same day. The Form 144 filing indicates these sales were executed on November 11 but reported on November 12 due to a federal holiday.

MIRM: Four approved medicines, with 2027 catalysts in HDV, PSC and PBC

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4576676:0-mirm-four-approved-medicines-with-2027-catalysts-in-hdv-psc-and-pbc/
Mirum Pharmaceuticals (MIRM) expects 2026 revenue guidance of $715M-$720M and anticipates being cash-flow-positive in 2027, driven significantly by ATEBRIOZ. The company has key pipeline milestones including a brelovitug filing next year and volixibat data in PBC in Q1 2027. This information is based on an AI-generated summary of Mirum Pharmaceuticals' Stifel 2026 Healthcare Conference audio transcript from November 11, 2026.

Mirum Pharmaceuticals (MIRM) Phase 3 Win Sets Up FDA Plans, Is It Still 38% Below Fair Value?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-phase-3-win-sets-up-fda-plans-is
Mirum Pharmaceuticals (MIRM) recently announced that its Phase 3 AZURE-4 trial for brelovitug met its primary endpoint, supporting a planned U.S. FDA filing for chronic hepatitis delta virus. Despite recent share price gains, analysts still consider the stock to be 38% undervalued, with a fair value of $153.43 compared to its closing price of $94.42. The company's expanding patient population and advances in precision medicine are expected to drive sustained revenue, though reliance on LIVMARLI and potential setbacks for other pipeline drugs present risks.

Citigroup maintains Mirum Pharmaceuticals at Buy, raises price target to $194 from $184

https://www.tradingview.com/news/tradingview:ea59af1428b40:0-citigroup-maintains-mirum-pharmaceuticals-at-buy-raises-price-target-to-194-from-184/
Citigroup has maintained its "Buy" rating for Mirum Pharmaceuticals and increased its price target to $194 from $184, representing a 5.4% rise. This new target suggests a potential upside of 105.5% from the closing price of $94.42 on November 10. Other analysts have also recently issued "Outperform" or "Buy" ratings for Mirum Pharmaceuticals with price targets ranging from $140 to $202.
Advertisement

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 3 Brelovitug Data

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-reports-positive-phase-3-brelovit
Mirum Pharmaceuticals (MIRM) announced positive Phase 3 results for brelovitug in chronic hepatitis delta virus, meeting its primary endpoint and potentially supporting a future FDA submission. This positive data strengthens Mirum's strategy of diversifying its rare-disease portfolio, which already includes LIVMARLI and Atebrioz. However, the company also faces challenges related to execution and spending for a new product launch, which analysts have flagged as risk factors.

Mirum Pharmaceuticals meets AZURE-4 Phase 3 endpoint

https://mugglehead.com/mirum-pharmaceuticals-azure-4-hepatitis-delta-phase-3-endpoint/
Mirum Pharmaceuticals announced that its AZURE-4 Phase 3 trial for hepatitis delta met its primary endpoint, with 59% of weekly brelovitug recipients achieving combined viral and liver-enzyme responses. The company plans to file for FDA approval in the first half of 2027. This success follows a similar positive outcome in the AZURE-1 study and positions Mirum for a potential U.S. launch in late 2027.

MIRM: Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

https://quantisnow.com/insight/mirum-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6782898
Mirum Pharmaceuticals Inc. announced that its investigational drug brelovitug met the primary endpoint in the Phase 3 AZURE-4 study for chronic hepatitis delta, marking a significant clinical milestone. The drug was well tolerated with no new safety signals, though approval is still pending future regulatory review. Response rates for the two dose groups were 59% and 44%, with flu-like illness being the most common adverse event.

Form 8K Mirum Pharmaceuticals Inc For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-mirum-pharmaceuticals-inc-for-10-november-93CH-4946425
Mirum Pharmaceuticals Inc. filed a Form 8K on November 10, 2026. The article from Investing.com announces this filing, which is a standard disclosure document used by publicly traded companies to notify investors of unscheduled material events or corporate changes. The stock symbol for Mirum Pharmaceuticals is MIRM, which showed a gain of 1.33% at the time of publication.

Form 8K Mirum Pharmaceuticals Inc For: 10 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-mirum-pharmaceuticals-inc-for-10-november-93CH-4971459
Mirum Pharmaceuticals Inc. filed a Form 8K on November 10, 2026. This filing, available through Investing.com, indicates a significant event or disclosure by the company. The article provides the basic announcement of the filing without further details on its content.
Advertisement

Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

https://www.stocktitan.net/news/MIRM/mirum-pharmaceuticals-announces-primary-endpoint-met-in-azure-4-s633skv6yxvo.html
Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study evaluating brelovitug for chronic hepatitis delta virus (HDV) met its primary endpoint, with 59% of patients achieving a combined virologic response and ALT normalization at Week 24. This marks the second successful Phase 3 study for brelovitug, supporting Mirum's planned U.S. Biologics License Application (BLA) submission in the first half of 2027. Long-term data from Phase 2 studies also presented at The Liver Meeting® demonstrated deepening viral suppression and improved liver stiffness with extended brelovitug treatment, even in patients with advanced cirrhosis, and a favorable safety profile across all studies.

MIRM: Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

https://www.quantisnow.com/insight/mirum-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6782898
Mirum Pharmaceuticals Inc. announced that its investigational drug, brelovitug, met the primary endpoint in the Phase 3 AZURE-4 study for chronic hepatitis delta. The drug was well tolerated with no new safety signals, marking a significant clinical milestone. However, approval is still subject to further regulatory review, and a notable percentage of patients did not respond to treatment.

Weekly Recap: Raised sales guidance and AZURE-1 meets primary endpoint

https://www.tradingview.com/news/tradingview:0297dd2f790ff:0-weekly-recap-raised-sales-guidance-and-azure-1-meets-primary-endpoint/
Mirum Pharmaceuticals (NASDAQ:MIRM) reported strong third-quarter 2026 product sales of $185.7 million, leading them to raise their full-year 2026 sales guidance to $715 million–$720 million. The company also announced that its brelovitug AZURE-1 Phase 3 trial successfully met its primary endpoint, with further trial results and an NDA filing for other treatments anticipated in late 2026 and early 2027. Analysts maintain a Buy consensus for MIRM, with an increased average 12-month price target.

Mirum Pharmaceuticals (MIRM) Opens No Cost Genetic Testing For Rare Liver Disease

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-opens-no-cost-genetic-testing-for
Mirum Pharmaceuticals has announced a collaboration with GeneDx to offer no-cost genetic testing for eligible patients with rare liver diseases. This initiative aims to facilitate earlier and more accurate diagnoses, aligning with Mirum's focus on rare disease treatments like Livmarli. While reinforcing Mirum's precision medicine narrative, the company continues to face significant reported losses.

Leerink Partners maintains Mirum Pharmaceuticals at Outperform, lowers price target to $140 from $154

https://www.tradingview.com/news/tradingview:6f5f8bf656a41:0-leerink-partners-maintains-mirum-pharmaceuticals-at-outperform-lowers-price-target-to-140-from-154/
Leerink Partners has maintained its "Outperform" rating for Mirum Pharmaceuticals but reduced its price target to $140 from $154, a 9.1% decrease. This new price target implies a 49.7% upside from the stock's closing price of $93.54 on November 5. Other analysts have recently issued price targets for Mirum Pharmaceuticals ranging from $145 to $202.
Advertisement

Mirum Pharmaceuticals (MIRM) Stock May Be About Right As Its 5 Year Run Draws Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-stock-may-be-about-right-as-its-5
Mirum Pharmaceuticals (MIRM) has seen its stock climb significantly over the past five years, prompting a focus on whether its current share price is justified by its sales and future revenue potential. The company's P/S ratio of 9.4x is below the biotech industry average, and the Fair Ratio model suggests its valuation is "about right." Investors are encouraged to assess the quality and durability of future revenue to determine if the current price is warranted.

H.C. Wainwright raises Mirum Pharmaceuticals price target to $202

https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-mirum-pharmaceuticals-price-target-to-202-93CH-4999058
H.C. Wainwright increased its price target for Mirum Pharmaceuticals (NASDAQ:MIRM) to $202 from $200, maintaining a Buy rating after the company reported strong third-quarter 2026 net product sales of $185.7 million. This performance, a 40% year-over-year increase, surpassed consensus estimates, driven largely by LIVMARLI sales. Despite an earnings per share miss, other firms like Raymond James and Citizens also raised their price targets, citing Mirum's continued commercial strength and diversified pipeline.

After exercising options, Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares at $90 each.

https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-a5dd8a4ffd58.html
Mirum Pharmaceuticals CEO Christopher Peetz exercised fully vested options for 20,000 common shares at $2.936 each and subsequently sold all 20,000 shares at $90 per share on November 4, 2026. This transaction, conducted under a Rule 10b5-1 plan adopted in March 2026, resulted in approximately $1.74 million in pre-tax spread. Following the sale, Peetz directly holds 206,637 common shares and indirectly holds 187,500 shares through The Peetz Family Trust.

Form 4 Mirum Pharmaceuticals Inc: Christopher Peetz (Director, CEO) For: 4 November

https://uk.investing.com/news/stock-market-news/form-4-mirum-pharmaceuticals-inc-christopher-peetz-director-ceo-for-4-november-93CH-4959109
This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc, detailing an insider transaction by Christopher Peetz, who serves as a Director and CEO. The transaction date is noted as November 4. The company's stock symbol is MIRM.

Mirum Raises 2026 Net Product Sales Guidance to $715 Million-$720 Million

https://www.tokenpost.com/news/business/48691
Mirum Pharmaceuticals, Inc. has increased its 2026 net product sales guidance to $715 million-$720 million, following strong third-quarter sales of $186 million. The company is targeting positive cash flow in 2027, driven by commercial performance and pipeline advancements, including the growth of LIVMARLI and the U.S. launch of Atebrioz. Mirum also plans to submit a new drug application for volixibat in the first half of 2027.
Advertisement

HC Wainwright & Co. maintains Mirum Pharmaceuticals at Buy, raises price target to $202 from $200

https://www.tradingview.com/news/tradingview:7daa7d65dc64a:0-hc-wainwright-co-maintains-mirum-pharmaceuticals-at-buy-raises-price-target-to-202-from-200/
HC Wainwright & Co. has reiterated its "Buy" rating for Mirum Pharmaceuticals and increased its price target from $200 to $202, representing a 1.0% raise. This new target implies a potential upside of 132.1% from the stock's closing price of $87.03 on November 3rd. Other recent analyst actions on Mirum Pharmaceuticals include maintained ratings and price targets ranging from $145 to $160.

Mirum Pharmaceuticals Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:724483:0-mirum-pharmaceuticals-q3-2026-earnings-call-is-live/
Mirum Pharmaceuticals's Q3 2026 earnings call has commenced, with executives discussing the latest financial results and addressing questions from analysts. This event is crucial for those following MIRM, as management commentary can significantly influence market perception, especially when future demand, margins, or capital spending are discussed.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

https://finance.yahoo.com/markets/stocks/articles/mirum-pharmaceuticals-inc-mirm-reports-211503780.html
Mirum Pharmaceuticals, Inc. (MIRM) reported a Q3 loss of $0.87 per share, significantly missing the Zacks Consensus Estimate of a $0.53 loss, and falling from earnings of $0.05 per share a year ago. Despite the loss, the company exceeded revenue estimates, posting $185.72 million against a consensus of $133.01 million, and has topped revenue estimates in four consecutive quarters. The stock currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market.

Mirum Pharmaceuticals, Inc. (MIRM) Misses Q3 EPS by 38c ; Offers Guidance

https://www.streetinsider.com/Earnings/Mirum+Pharmaceuticals%2C+Inc.+%28MIRM%29+Misses+Q3+EPS+by+38c+%3B+Offers+Guidance/27281558.html
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported its Q3 earnings, missing analyst estimates for EPS by $0.38 with a reported ($0.87) against an estimated ($0.49). Despite the EPS miss, the company's revenue of $185.7 million surpassed the consensus estimate of $178.06 million. Mirum also provided optimistic FY2026 revenue guidance, projecting $715-720 million, which is above the consensus of $698.1 million.

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026

https://www.stocktitan.net/news/MIRM/mirum-pharmaceuticals-showcases-momentum-across-rare-liver-disease-d61vguf8kcs2.html
Mirum Pharmaceuticals announced it will present new data from its rare liver disease portfolio at The Liver Meeting® 2026, highlighting longer-term brelovitug responses in chronic hepatitis delta virus (HDV), including patients with cirrhosis, and volixibat itch findings in primary sclerosing cholangitis (PSC). The presentations will reinforce the efficacy and safety profiles of its investigational programs and provide new insights into LIVMARLI® (maralixibat) treatment outcomes in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). These updates underscore Mirum's commitment to addressing significant unmet needs in rare liver diseases.
Advertisement

Weekly Recap: Positive zilurgisertib Week 24 results and ATEBRIOZ FDA plans

https://www.tradingview.com/news/tradingview:da3ffa13ec908:0-weekly-recap-positive-zilurgisertib-week-24-results-and-atebrioz-fda-plans/
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced positive Week 24 results for zilurgisertib in children with FOP, showing reduced lesion volume and no new lesions or safety signals. The company plans FDA discussions and an H1 2027 filing to expand ATEBRIOZ approval to children aged 6 to under 12. Mirum is also scheduled to report its Q3 2026 results on November 3rd.

Mirum Pharmaceuticals (MIRM) Climbed, So What Is Behind The Move?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-climbed-so-what-is-behind-the-mov
Mirum Pharmaceuticals (MIRM) saw a 2.75% share price increase after reporting positive 24-week outcomes from its PROGRESS trial for ATEBRIOZ in children with fibrodysplasia ossificans progressiva. Despite a recent 24.01% decline over 90 days, the stock has a strong three-year return of 201.06% and is considered 44% undervalued with a fair value estimate of $153.07, driven by multiple late-stage pipeline catalysts. However, the company faces risks related to Livmarli concentration and potential regulatory delays for volixibat.

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

https://ca.finance.yahoo.com/news/mirum-pharmaceuticals-inc-mirm-expected-130017070.html
Mirum Pharmaceuticals, Inc. (MIRM) is anticipated to surpass earnings estimates for the quarter ended September 2026, despite expectations of a year-over-year decline in earnings per share but higher revenues. The company's Zacks Earnings ESP of +56.93% combined with a Zacks Rank #3 suggests a high probability of an earnings beat, as analysts have recently become more bullish on its prospects. Investors are advised to consider the Earnings ESP and Zacks Rank as key indicators for potential stock movement ahead of the official Q3 release.

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

https://www.stocktitan.net/news/MIRM/mirum-pharmaceuticals-announces-positive-results-from-cohort-2-of-h7xt29bp7x4o.html
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study for ATEBRIOZ™ (zilurgisertib) in pediatric FOP patients aged 6 to under 12 years. The study showed zilurgisertib significantly reduced total heterotopic ossification (HO) lesion volume and improved joint mobility, with no new HO lesions developing in treated patients. Mirum plans to submit a supplemental New Drug Application in the first half of 2027 to expand ATEBRIOZ's indication to this younger pediatric population.

Form 8K Mirum Pharmaceuticals Inc For: 26 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-mirum-pharmaceuticals-inc-for-26-october-93CH-2758338
Mirum Pharmaceuticals Inc. filed a Form 8K on October 26, 2026. This filing is a standard notification used to announce major events that shareholders should know about. The article mentions the company's stock symbol, MIRM, which showed a 3.58% increase at the time of publication.
Advertisement

Form 8K Mirum Pharmaceuticals Inc For: 26 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-mirum-pharmaceuticals-inc-for-26-october-93CH-4932515
Mirum Pharmaceuticals Inc. filed a Form 8K on October 26, 2026. This filing, reported by Investing.com, likely contains significant information that could impact the company's stock, which saw a 3.58% increase according to the article. The article itself is very brief, primarily serving as an announcement of the filing.

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

https://www.financialcontent.com/article/bizwire-2026-10-26-mirum-pharmaceuticals-announces-positive-results-from-cohort-2-of-the-pivotal-progress-study-of-atebrioz-zilurgisertib-in-pediatric-patients-aged-6-to-12-years-with-fibrodysplasia-ossificans-progressiva
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study for ATEBRIOZ™ (zilurgisertib) in pediatric patients aged 6 to <12 years with fibrodysplasia ossificans progressiva (FOP). The study showed that zilurgisertib reduced total heterotopic ossification (HO) lesion volume and improved joint mobility, with no new HO lesions observed in treated patients. Mirum plans to submit a supplemental New Drug Application (sNDA) in the first half of 2027 to expand the ATEBRIOZ indication to this younger pediatric population, building on its existing FDA approval for patients aged 12 and older.

Form 8K Mirum Pharmaceuticals Inc For: 26 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-mirum-pharmaceuticals-inc-for-26-october-93CH-4904022
This article announces that Mirum Pharmaceuticals Inc. filed a Form 8K on October 26, 2026. The filing is an important regulatory disclosure for investors and the broader market.

Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Positive Pediatric ATEBRIOZ Trial Results

https://kalkine.com.au/news/healthcare/mirum-pharmaceuticals-nasdaqmirm-reports-positive-pediatric-atebrioz-trial-results
Mirum Pharmaceuticals announced positive results from Cohort 2 of its PROGRESS study for ATEBRIOZ in children aged six to under 12 with fibrodysplasia ossificans progressiva. The trial showed a significant reduction in abnormal bone lesion volume, improved joint mobility, and no new lesions in treated patients. Mirum plans to submit a supplemental New Drug Application in the first half of 2027 to expand the drug's indication to this younger age group.

Mirum Pharmaceuticals, Inc. Estimates – NASDAQ:MIRM

https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-estimates/
This page provides an overview of Mirum Pharmaceuticals, Inc. (MIRM) financial estimates on TradingView. It allows users to explore reported financial data and analyst estimates for income statements, balance sheets, cash flow, and valuation metrics, enabling comparison of actual results with average, high, and low estimates. The platform also visualizes financial trends over time for both annual and quarterly data.
Advertisement

How Investors May Respond To Mirum Pharmaceuticals (MIRM) Phase 3 Trial Success

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/how-investors-may-respond-to-mirum-pharmaceuticals-mirm-phas-1
Mirum Pharmaceuticals (MIRM) announced positive topline Phase 3 EXPAND data for LIVMARLI, showing significant itch reduction and bile acid lowering in ultra-rare cholestatic liver diseases. This success supports the potential expansion of LIVMARLI's label and use, aligning with analyst expectations for substantial revenue and earnings growth by 2029. The data provides a key catalyst for the company, influencing its investment narrative and upcoming discussions with regulators and payers.

Mirum Pharmaceuticals, Inc. Estimates – BOATS:MIRM

https://www.tradingview.com/symbols/BOATS-MIRM/financials-estimates/
This article provides an overview of Mirum Pharmaceuticals, Inc. (MIRM) financial estimates available on TradingView, specifically through the Blue Ocean Alternative Trade System (BOATS). It highlights access to reported financial data and analyst estimates across income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with various estimates and visualize trends. The platform offers annual and quarterly data for comprehensive financial analysis.

Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/MIRM/
This article provides a comprehensive overview of Mirum Pharmaceuticals, Inc. (MIRM), including its current stock price, key financial statistics, and recent news. Mirum, a biopharmaceutical company, focuses on developing therapies for rare and orphan diseases, with its lead product LIVMARLI approved for cholestatic pruritus in Alagille syndrome. Recent news highlights include positive Phase 3 trial results for LIVMARLI and Brelovitug, and FDA approval for Atebrioz for fibrodysplasia ossificans progressiva.

TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $145

https://www.moomoo.com/news/post/1001878056/td-cowen-maintains-mirum-pharmaceuticals-mirmus-with-buy-rating-raises
TD Cowen has reiterated its Buy rating for Mirum Pharmaceuticals (MIRM.US) and increased its target price for the stock to $145. This indicates a positive outlook from the analyst firm regarding Mirum Pharmaceuticals' future performance.

Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history

https://au.finance.yahoo.com/quote/MIRM/
This article provides a comprehensive overview of Mirum Pharmaceuticals, Inc. (MIRM), detailing its stock performance, key financial metrics, and corporate profile. It highlights the company's focus on developing therapies for rare and orphan diseases, including its lead product LIVMARLI, and outlines its pipeline of other drug candidates. The report also includes analyst insights and recent earnings trends.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement